Equilibrium dissociation constants determined by ITC for each reversal agent titrated into various potential binding partners
| Putative binding partner . | Kd (M) . | ||
|---|---|---|---|
| UHRA . | Andexanet alfa . | Ciraparantag . | |
| UFH | 8.9 (± 0.3) × 10−7 | 3.4 (± 0.4) × 10−5 | 2.8 (± 0.3) × 10−5 |
| Enoxaparin | 6.0 (± 0.4) × 10−6 | 4.0 (± 0.3) × 10−5 | 1.7 (± 0.3) × 10−5 |
| Enoxaparin–AT complex | — | 7.1 (± 0.5) × 10−7 | 6.9 (± 2.8) × 10−4 |
| Fondaparinux | 2.4 (± 0.6) × 10−6 | 1.1 (± 2.0) × 10−4 | 9.6 (± 3.9) × 10−3 |
| Edoxaban | ND | 3.4 (± 0.6) × 10−9 | NB |
| Rivaroxaban | ND | 0.9 (± 0.2) × 10−9 | NB |
| h-FXa | NB | NB | NB |
| h-FIX | — | — | NB |
| h-FIXa | — | — | 3.5 (± 0.4) × 10−5 |
| h-thrombin | NB | — | NB |
| h-antithrombin | NB | — | NB |
| h-fibrinogen | NB | NB | NB |
| Putative binding partner . | Kd (M) . | ||
|---|---|---|---|
| UHRA . | Andexanet alfa . | Ciraparantag . | |
| UFH | 8.9 (± 0.3) × 10−7 | 3.4 (± 0.4) × 10−5 | 2.8 (± 0.3) × 10−5 |
| Enoxaparin | 6.0 (± 0.4) × 10−6 | 4.0 (± 0.3) × 10−5 | 1.7 (± 0.3) × 10−5 |
| Enoxaparin–AT complex | — | 7.1 (± 0.5) × 10−7 | 6.9 (± 2.8) × 10−4 |
| Fondaparinux | 2.4 (± 0.6) × 10−6 | 1.1 (± 2.0) × 10−4 | 9.6 (± 3.9) × 10−3 |
| Edoxaban | ND | 3.4 (± 0.6) × 10−9 | NB |
| Rivaroxaban | ND | 0.9 (± 0.2) × 10−9 | NB |
| h-FXa | NB | NB | NB |
| h-FIX | — | — | NB |
| h-FIXa | — | — | 3.5 (± 0.4) × 10−5 |
| h-thrombin | NB | — | NB |
| h-antithrombin | NB | — | NB |
| h-fibrinogen | NB | NB | NB |
Data are presented as mean ± SE.
h, human; NB, no binding detected; ND, not determined.